NCNina Cohen

Nina Cohen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Nina Cohen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sepsis and postoperative surgical site infections

    by Nina S. Cohen, Jiselle M. Bock, Addison K. May


  • Open Access

    Predictors of Coronavirus Disease 2019 Hospitalization After Sotrovimab in Patients With Hematologic Malignancy During the BA.1 Omicron Surge

    by Judy Yan, Samantha N Steiger, Rich Kodama, Jerome Fender, Carrie Tan, Justin Laracy, Nina Cohen, Tracy McMillen, Krupa Jani, Elizabeth V Robilotti, et al.

    Sotrovimab is an anti-spike neutralization monoclonal antibody developed to reduce the risk of coronavirus disease 2019 (COVID-19) progression and advancement to hospitalization in high-risk patients. Currently, there is limited research describing the association of sotrovimab treatment in patients with hematologic malignancy and the predictive factors of hospitalization. We performed an observational study of 156 consecutive cancer patients who received sotrovimab at Memorial Sloan Kettering Cancer Center in New York City during the BA.1 Omicron surge. We evaluated the demographic, clinical, and laboratory characteristics of the patients who had subsequent COVID-19–related hospitalization(s) compared to those who did not. Among the 156 study patients, 17 (11%) were hospitalized, of whom 4 were readmitted for COVID-19–related complications; 3 deaths were attributed to COVID-19. Results from multivariable logistic regression show that significant factors associated with hospitalization include patients on anti-CD20 therapy (adjusted odds ratio [aOR], 5.59 [95% confidence interval {CI}, 1.73–18.12]; P = .004) and with relapse/refractory disease (aOR, 5.69 [95% CI, 1.69–19.16]; P = .005). Additionally, whole genome sequencing of severe acute respiratory syndrome coronavirus 2 detected high occurrences of mutations in the spike gene associated with treatment-related resistance longitudinal samples from 11 patients treated with sotrovimab. While sotrovimab is effective at reducing COVID-19 hospitalization and disease severity in patients with hematologic malignancy when administered early, patients who received anti-CD20 antibodies showed substantial morbidity. Due to the high potential for resistance mutation to sotrovimab and increased morbidity in patients on anti-CD20 therapy, combination treatment should be explored to determine whether it provides added benefits compared to monotherapy.


  • Open Access

    434Prevalence, Risk Factors, and Outcomes of Bacteremia Caused by Carbapenem-resistant Enterobacteriaceae in Neutropenic Patients with Hematologic Malignancies

    by Michael J. Satlin, Nina Cohen, Kevin C. Ma, Zivile Gedrimaite, Thomas J. Walsh, Susan K. Seo

    Background. Neutropenic patients with hematologic malignancies rely on immediate, active antimicrobial therapy to combat bacterial infections, and thus are uniquely threatened by multidrug-resistant bacteria. Carbapenem-resistant Enterobacteriaceae (CRE) have emerged worldwide and are resistant to nearly all antimicrobial agents, but their impact on neutropenic patients is unknown.